Similar regimens are being tested in ongoing studies, some noteworthy trials are Mosunetuzumab with Polatuzumab vedotin and Obinutuzumab (NCT05169658) in untreated indolent B-cell lymphomas, Tazemetostat (EZH2 inhibitor) with Mosunetuzumab (NCT05994235) in newly diagnosed follicular lymphoma, Glofitamab with Obinutuzumab (NCT05783596) in untreated follicular lymphoma, and Mosunetuzumab with Lenalidomide in relapsed follicular lymphoma (NCT04712097)/relapsed Marginal zone lymphoma (NCT06006117). Here, EZH2 is linked to marginal zone lymphoma.